MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$11,120K
Free Cash flow
-$31,142K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Stock-based compensation
Accounts payable, accrued expens...
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Prepaid expenses and other asset...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-45,558
-39,305
-33,834
-86,113
Depreciation
138
138
132
414
Stock-based compensation
10,232
7,847
7,627
20,379
Accretion on marketable securities, net
-205
-25
-126
-1,993
Prepaid expenses and other assets
1,018
2,438
-404
5,484
Accounts payable, accrued expenses and other liabilities
5,318
1,195
2,156
1,213
Right-of-use assets and lease liabilities, net
17
17
17
66
Net cash used in operating activities
-31,076
-32,571
-23,624
-71,518
Purchases of marketable securities
22,080
162,206
9,106
92,148
Maturities of marketable securities
40,000
42,050
43,540
130,318
Purchases of property and equipment
66
88
57
84
Net cash provided by (used in) investing activities
17,854
-120,244
34,377
38,086
Proceeds from issuances of common stock under benefit plans
2,102
12,530
4,683
3,417
Proceeds from issuance of common stock and pre-funded warrants from private placement
-
-
0
0
Payments of issuance costs for common stock and pre-funded warrants from private placement
-
-
0
0
Proceeds from issuances of common stock under at-the-market offering program, net of 2.1 million of issuance costs
0
147,853
-
-
Net cash provided by financing activities
2,102
160,383
4,683
3,417
Net cash increase (decrease) for the period
-11,120
7,568
15,436
-30,015
Cash, cash equivalents and restricted cash at beginning of the period
85,955
78,387
99,490
99,490
Cash, cash equivalents and restricted cash at end of the period
74,835
85,955
78,387
62,951
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$40,000K
Proceeds from issuances
of common stock...
$2,102K
Net cash provided by
(used in) investing...
$17,854K
Net cash provided by
financing activities
$2,102K
Canceled cashflow
$22,146K
Net cash increase
(decrease) for the period
-$11,120K
Canceled cashflow
$19,956K
Stock-based compensation
$10,232K
Accounts payable,
accrued expenses and...
$5,318K
Depreciation
$138K
Right-of-use assets and lease
liabilities, net
$17K
Purchases of marketable
securities
$22,080K
Purchases of property and
equipment
$66K
Net cash used in
operating activities
-$31,076K
Canceled cashflow
$15,705K
Net loss
-$45,558K
Prepaid expenses and
other assets
$1,018K
Accretion on marketable
securities, net
-$205K
Buy us a coffee
Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA)